Stocks to Watch: United Airlines, J.B. Hunt, Autodesk
By Dean Seal
United Airlines reported a 10% revenue jump to $12.5 billion in the first quarter, topping analyst forecasts. The top line was boosted by strong demand for flights, with a double-digit percentage rise in business travel demand compared with the prior quarter. Shares rose 5% to $43.60 after hours.
J.B. Hunt Transport Services' profit and revenue fell in the first quarter as demand for its domestic intermodal service softened more than expected and trucking volumes fell in a weak U.S. freight market. Both the top and bottom lines missed analyst expectations. Shares fell 5.2% to $173.44 in after-market trading.
Autodesk said a probe of its accounting practices is continuing and that it won't be able to file its annual report with regulators within a given extension period. Shares slide 2.8% to $221.96 after hours post-market.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 16, 2024 19:08 ET (23:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track